-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
TB-500 10mg is a synthetic research peptide studied in relation to thymosin beta-4 fragment research, actin pathway models, cell migration research, tissue-remodelling pathway studies, angiogenesis-related models and wound-response research contexts.
Analytical literature has identified TB-500 as the N-terminal acetylated 17-23 fragment of human thymosin beta-4, commonly written as Ac-LKKTETQ.
This should be understood as laboratory and analytical research context only. It should not be used as a claim that a research-use TB-500 vial has proven human benefits or is suitable for injury recovery, sport, wound healing, muscle repair or human administration.
| Product Detail | Information |
|---|---|
| Product name | TB-500 |
| Common research names | TB-500, thymosin beta-4 fragment, Tβ4 fragment |
| Size | 10mg |
| Product type | Research peptide |
| Research category | Tissue Remodelling Research / Actin Pathway Research |
| Common research interest | Actin binding, cell migration, angiogenesis-related models and tissue-response pathway research |
| Peptide type | Synthetic acetylated heptapeptide fragment |
| Common sequence reference | Ac-LKKTETQ |
| Parent peptide context | Thymosin beta-4 |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, injury recovery, tissue repair, wound healing, sport use or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| TB-500 | Synthetic research peptide | Studied in relation to thymosin beta-4 fragment pathway research |
| Ac-LKKTETQ | N-terminal acetylated heptapeptide sequence | Identified in analytical literature as the 17-23 fragment of thymosin beta-4 |
| Thymosin beta-4 context | Parent peptide research context | Full-length thymosin beta-4 is commonly discussed in actin and cell migration research |
| Actin-binding motif context | Cytoskeletal pathway research | Relevant to actin organisation and cell migration models |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
| Batch-specific identity | CoA-dependent | Sequence, purity, salt form and assay result must be confirmed by documentation |
Product identity, sequence, acetylation status, purity, salt form and batch information should always be confirmed through supplier documentation and the Certificate of Analysis. TB-500 should not be treated as identical to full-length thymosin beta-4 unless documentation specifically supports the material being supplied.
TB-500 is studied as a thymosin beta-4 fragment research peptide. In laboratory settings, thymosin beta-4 and related fragments are commonly discussed in relation to actin binding, cytoskeletal organisation, cell migration, angiogenesis-related models and tissue-remodelling pathway research.
A PubMed review describes thymosin beta-4 as binding to actin and promoting cell migration, including mobilisation, migration and differentiation of progenitor cells in tissue-regeneration research contexts.
However, full-length thymosin beta-4 literature should not be automatically applied to TB-500 research vials. TB-500 is commonly discussed as a fragment, so product pages should clearly separate parent-peptide research from fragment-specific product identity.
| Research Area | TB-500 |
| Main research category | Thymosin beta-4 fragment research |
| Common sequence reference | Ac-LKKTETQ |
| Peptide length | Heptapeptide fragment |
| Parent peptide context | Thymosin beta-4 |
| Common pathway interest | Actin binding, cell migration and tissue-remodelling research |
| Wound-response research interest | Preclinical wound-response and cellular migration models |
| Angiogenesis research interest | Blood vessel formation and cell movement pathway models |
| Anti-doping context | Prohibited in sport at all times under Sport Integrity Australia / WADA context |
| Product limitation | Research use only, not approved for human use |
| Feature | TB-500 | Thymosin Beta-4 |
| Research class | Synthetic thymosin beta-4 fragment research peptide | Full-length endogenous peptide hormone research context |
| Common sequence reference | Ac-LKKTETQ | Full 43-amino-acid peptide context |
| Main research focus | Fragment-specific actin and cell migration pathway research | Broader actin, immune, cell migration and tissue-response research |
| Product identity risk | Mistaken for full-length TB4 | Mistaken for TB-500 fragment |
| SEO risk | Injury recovery and performance claims | Tissue repair and therapeutic claims |
| Safer positioning | Thymosin beta-4 fragment research peptide | Full-length thymosin beta-4 research context |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | TB-500 | BPC-157 |
| Research class | Thymosin beta-4 fragment research peptide | Stable gastric pentadecapeptide research peptide |
| Main research focus | Actin, cell migration and tissue-remodelling pathway research | Cytoprotection, angiogenesis and gastric peptide pathway research |
| Peptide type | Synthetic acetylated heptapeptide fragment | Synthetic 15-amino-acid peptide |
| Common research overlap | Wound-response and soft tissue pathway models | Wound-response and soft tissue pathway models |
| Common SEO risk | Injury recovery, muscle repair and sport claims | Injury recovery, tendon repair and gut-healing claims |
| Safer positioning | Cell migration and actin pathway research | Gastric pentadecapeptide pathway research |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | TB-500 | GHK-Cu |
| Research class | Thymosin beta-4 fragment research peptide | Copper peptide complex |
| Main research focus | Actin, cell migration and tissue-remodelling research | Extracellular matrix, copper biology and skin pathway research |
| Common overlap | Wound-response and tissue-remodelling models | Wound-response and extracellular matrix models |
| Key pathway | Actin and cell migration research | Copper coordination and matrix pathway research |
| Common SEO risk | Injury recovery and healing claims | Skincare, collagen and anti-ageing claims |
| Safer positioning | Thymosin beta-4 fragment research | Copper peptide research compound |
| Product | Safer Research Positioning |
| TB-500 10mg | Thymosin beta-4 fragment, actin and cell migration pathway research |
| BPC-157 10mg | Gastric pentadecapeptide, cytoprotection and angiogenesis pathway research |
| GHK-Cu 50mg | Copper peptide, extracellular matrix and tissue-remodelling pathway research |
| KPV 10mg | Tripeptide inflammatory pathway and melanocortin-related research |
| SS-31 10mg | Mitochondrial membrane and cardiolipin pathway research |
These products should not be written as if they are interchangeable. TB-500 should be positioned around thymosin beta-4 fragment and cell migration pathway research, not human injury recovery, sport use or therapeutic repair.
| Common Online Claim | Safer Research-Use Wording |
| Injury recovery | Studied in tissue-response and cell migration pathway research models |
| Muscle repair | Not an approved or appropriate product claim |
| Tendon healing | Better framed as soft tissue and cell migration research models |
| Ligament repair | Not an approved or appropriate product claim |
| Wound healing | Better framed as wound-response research models |
| Faster recovery | Not an approved or appropriate product claim |
| Sports performance | Not suitable for research-use product positioning |
| Anti-inflammatory support | Better framed as inflammatory pathway research context only |
| Tissue regeneration | Better framed as tissue-remodelling pathway research |
TB-500 10mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for injury recovery, muscle repair, tendon repair, ligament repair, wound healing, pain relief, inflammation, sports recovery, bodybuilding, athletic performance, tissue repair, general wellness or therapeutic use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for TB-500 10mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, salt form, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 10mg Vial | Final Concentration |
| 1mL | 10mg/mL |
| 2mL | 5mg/mL |
| 2.5mL | 4mg/mL |
| 3mL | 3.33mg/mL |
| 4mL | 2.5mg/mL |
| 5mL | 2mg/mL |
| 10mL | 1mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities, treatment quantities, recovery plans or administration schedules.
Before handling TB-500 10mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised TB-500 peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Sequence or identity confirmation | Helps confirm the product is TB-500 / thymosin beta-4 fragment |
| Acetylation confirmation | Helps confirm fragment identity where documented |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis, peptide identity and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Product identity unclear | Possible peptide mix-up or fragment/full-length confusion | Stop and confirm CoA before using |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Variant control | Store and label separately from BPC-157, GHK-Cu and full-length thymosin beta-4 products |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record product name, concentration, date, diluent and batch number |
| Sequence or fragment tracking | Record TB-500 / thymosin beta-4 fragment identity where documented |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules, injury recovery schedules, sport-use guidance or administration guidance.
TB-500 10mg is not supplied for human or animal administration. It is a laboratory research-use product only.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Peptide identity | Confirmation that the product is TB-500 |
| Fragment confirmation | Ac-LKKTETQ or supplier-documented thymosin beta-4 fragment identity |
| Salt form | Supplier-specific salt form, where documented |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 10mg vial strength matches the approved research protocol |
| Compliance check | Confirmation that no injury recovery, sports-use or injection wording is attached to the material |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded, storage conditions are not followed or human recovery claims are mixed into research-use product pages.
Because TB-500 is commonly discussed online in relation to tissue repair, injury recovery and sport, product pages should avoid wording that could be interpreted as encouraging human self-use, injection, athletic use, treatment use or performance enhancement.
Sport Integrity Australia states that thymosin beta-4, also known as TB4 or TB-500, is prohibited in sport at all times.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Confirm peptide identity | Helps verify the product is TB-500 |
| Confirm fragment or sequence details where documented | Helps distinguish TB-500 from full-length thymosin beta-4 |
| Confirm salt form where documented | Supports correct research calculations |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Avoid sport, recovery and performance wording | Reduces anti-doping and compliance risk |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as an injury recovery product | Creates human-use and compliance risk |
| Never make tissue repair or wound-healing claims | Not an approved or appropriate product claim |
| Never make muscle, tendon or ligament repair claims | Not suitable for a research-use product page |
| Never make pain relief or inflammation treatment claims | Not an approved or appropriate product claim |
| Never make sports recovery or performance claims | Creates compliance and anti-doping risk |
| Never market to athletes or bodybuilders | Creates human-use and anti-doping risk |
| Never imply therapeutic equivalence to any medicine | Misleading and not appropriate |
| Never assume TB-500 is the same as full-length thymosin beta-4 | Fragment identity matters |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity, treatment quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 10mg | 1mL | 10mg/mL |
| 10mg | 2mL | 5mg/mL |
| 10mg | 2.5mL | 4mg/mL |
| 10mg | 3mL | 3.33mg/mL |
| 10mg | 4mL | 2.5mg/mL |
| 10mg | 5mL | 2mg/mL |
| 10mg | 10mL | 1mg/mL |
If a researcher adds 2mL of suitable research-grade diluent to a 10mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example, treatment example, injection example, injury recovery example or sport-use instruction.
TB-500 is a synthetic research peptide commonly discussed as a thymosin beta-4 fragment. Analytical literature has identified TB-500 as the N-terminal acetylated 17-23 fragment of human thymosin beta-4, commonly written as Ac-LKKTETQ.
No. TB-500 is commonly described as a fragment associated with thymosin beta-4, while thymosin beta-4 refers to the full-length parent peptide context. Product identity should always be confirmed through the Certificate of Analysis.
TB-500 is commonly studied in relation to thymosin beta-4 fragment research, actin binding, cell migration, tissue-remodelling pathway models and wound-response research contexts.
No. This research product is not approved or supplied for injury recovery, wound healing, tissue repair, tendon repair, ligament repair, muscle repair, pain relief, sports recovery or human administration. It should be described only as a laboratory research product.
Sport Integrity Australia lists thymosin beta-4, also known as TB4 or TB-500, as prohibited in sport at all times under the 2026 World Anti-Doping Code Prohibited List.
No. TB-500 is commonly positioned around thymosin beta-4 fragment, actin and cell migration pathway research. BPC-157 is a stable gastric pentadecapeptide research peptide studied in cytoprotection and tissue-response pathway models.
No. TB-500 is a thymosin beta-4 fragment research peptide. GHK-Cu is a copper peptide complex studied in extracellular matrix, skin pathway and tissue-remodelling research.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity, salt form, sequence, fragment status and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| TB-500 analytical identification study | Useful background on the identification of TB-500 as the N-terminal acetylated 17-23 fragment of human thymosin beta-4, Ac-LKKTETQ. |
| Thymosin beta-4 regenerative peptide review | Useful background on thymosin beta-4, actin binding, cell migration and tissue-response research context. |
Research Use Only: TB-500 10mg is supplied strictly for laboratory research purposes. It is not intended for human or animal consumption, injection, therapeutic use, cosmetic use, diagnostic use, injury recovery, muscle repair, tendon repair, ligament repair, wound healing, pain relief, inflammation, sports recovery, bodybuilding, athletic performance, body enhancement or performance enhancement. Information on this page is provided for research education and product handling context only. Always follow applicable laws, institutional procedures, supplier documentation, SDS guidance and qualified laboratory protocols.
